Table 3.
Baseline characteristics in belatacept cohort by status for treatment success or failure censored for death. Treatment failure was defined as graft failure or GFR deterioration compared to the time of conversion
| Patient characteristics | All patients (N = 30) | Treatment success at 12 months (N = 16) | Treatment failure at 12 months (N = 13) | P value | Treatment success at 24 months (N = 12) | Treatment failure at 24 months (N = 15) | P value |
|---|---|---|---|---|---|---|---|
| Age (y) | 53.5 ± 26 | 53.5 ± 26 | 50 ± 29 | 0.983 | 52 ± 18 | 50 ± 30 | 0.829 |
| Donor age (y) | 48 ± 23 | 46.5 ± 31 | 46 ± 22 | 0.689 | 43 ± 26 | 52.5 ± 23 | 0.134 |
| Gender (m/f) | 20/10 | 11/5 | 8/5 | 0.714 | 10/2 | 7/8 | 0.107 |
| Post-transplant diabetes | 3/30 | 2/16 | 1/13 | 1.000 | 1/12 | 2/15 | 1.000 |
| BMI | 25.3 ± 4.1 | 24.7 ± 4.0 | 25.5 ± 6.1 | 0.650 | 24.7 ± 4.0 | 25.3 ± 7.9 | 0.100 |
| Systolic BP (mmHg) | 134 ± 17 | 139 ± 24 | 133 ± 18 | 0.199 | 139 ± 27 | 132 ± 14 | 0.183 |
| Diastolic BP (mmHg) | 84 ± 10 | 85 ± 10 | 84 ± 12 | 0.812 | 88.5 ± 12 | 83 ± 13 | 0.300 |
| Time after transplantation (m) | 127.5 ± 91.3 | 128.5 ± 148.8 | 127 ± 60 | 0.619 | 133.5 ± 125.8 | 126 ± 74 | 0.300 |
| eGFR (mL/min) | 22.5 ± 12 | 25 ± 12 | 20 ± 10 | 0.449 | 25.5 ± 14 | 20.0 ± 12 | 0.126 |
| eGFR < 25 mL/min | 17/30 | 7/16 | 10/13 | 0.130 | 5/12 | 11/15 | 0.130 |
| Proteinuria (mg/g creatinine) | 840 ± 1166 | 647 ± 1125 | 890 ± 1857 | 0.398 | 452 ± 1125 | 869 ± 1592 | 0.399 |
| Living donor transplants | 8/30 | 3/16 | 5/13 | 0.406 | 3/12 | 4/15 | 1.000 |
| pancreas/kidney | 2/30 | – | – | – | |||
| Immunosuppression | |||||||
| Tacrolimus | 22/30 | 12/4 | 9/4 | 1.000 | 9/12 | 10/15 | 0.696 |
| Cyclosporine A | 8/30 | 4/12 | 4/9 | 1.000 | 3/12 | 5/15 | 0.696 |
| Mycophenolic acid | 27/30 | 13/3 | 13/0 | 0.232 | 10/12 | 15/15 | 0.188 |
| Azathioprin | 2/30 | 2/14 | 0/13 | 0.488 | 1/12 | 0/15 | 0.444 |
| Steroid | 24/30 | 13/3 | 10/3 | 1.000 | 10/12 | 11/15 | 0.662 |
| DSA | 14/30 | 7/16 | 6/13 | 1.000 | 5/12 | 7/15 | 1.000 |
| h/o any rejection | 15/30 | 6/16 | 9/13 | 0.139 | 6/12 | 8/15 | 1.000 |
| aTCMR | 3/30 | 1/16 | 2/13 | 0.573 | 1/12 | 2/15 | 1.000 |
| aABMR | 6/30 | 1/16 | 5/13 | 0.064 | 1/12 | 5/15 | 0.182 |
| Biopsy scores | |||||||
| Glomerular scarring (%) | 30.5 ± 33 | 26 ± 29 | 32 ± 35.5 | 0.423 | 27 ± 33 | 32 ± 36 | 0.829 |
| Cg | 0.0 ± 3.0 | 0.0 ± 2.6 | 1.0 ± 3.0 | 0.288 | 0.0 ± 1.1 | 1.0 ± 3.0 | 0.236 |
| ct | 1.0 ± 1.0 | 1.0 ± 1.0 | 1.0 ± 2.0 | 0.983 | 1.0 ± 1.0 | 1.0 ± 1.0 | 0.548 |
| ci | 1.0 ± 1.0 | 1.0 ± 1.0 | 1.0 ± 1.0 | 0.846 | 1.0 ± 1.0 | 1.0 ± 1.0 | 0.683 |
| cv | 2.0 ± 2.0 | 2.0 ± 2.0 | 2.0 ± 2.0 | 0.339 | 2.0 ± 3.0 | 2.0 ± 1.0 | 0.959 |
| mm | 1.0 ± 2.0 | 0.0 ± 1.8 | 1.0 ± 1.5 | 0.170 | 0.0 ± 1.8 | 1.0 ± 2.0 | 0.373 |
| ah | 3.0 ± 0.0 | 3.0 ± 0.0 | 3.0 ± 0.5 | 0.650 | 3.0 ± 0.4 | 3.0 ± 0.0 | 0.581 |
| g | 0.0 ± 1.0 | 0.0 ± 0.8 | 0.0 ± 1.8 | 0.589 | 0.0 ± 0.8 | 0.0 ± 1.5 | 0.581 |
| t | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 1.0 | 0.589 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.829 |
| i | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 1.0 | 0.156 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.905 |
| v | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 1.000 | 0.0 ± 0.0 | 0.0 ± 0.0 | 1.000 |
| ptc | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 2.0 | 0.170 | 0.0 ± 0.0 | 0.0 ± 1.0 | 0.256 |
| C4d | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.948 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.981 |
| MVI sum score | 0.0 ± 1.3 | 0.0 ± 0.8 | 0.0 ± 2.8 | 0.144 | 0.0 ± 0.8 | 0.0 ± 2.5 | 0.183 |
| MVI sum score ≧2 | 7/30 | 1/16 | 6/13 | 0.026 | 1/12 | 6/15 | 0.091 |
Data were expressed as medians (interquartile range), or numbers
BMI body mass index, BP blood pressure, eGFR estimated glomerular filtration rate, DSA donor specific antibodies, h/o history of, aTCMR active T cell mediated rejection, aABMR active antibody-mediated rejection, MVI microvascular inflammation